10-Q: Bio Green Med Solution Pivots to Fire Safety, Reduces Loss

Bio Green Med Solution, Inc. has completed a strategic pivot from biopharmaceuticals to fire safety and distribution, reporting a significantly reduced net loss for the nine months ended September 30, 2025, following key acquisitions and divestitures.

Summary

• The company completed a strategic pivot from biopharmaceutical to fire safety and distribution, exiting its previous industry focus.
• Acquired Fitters Sdn. Bhd., a Malaysian fire safety company, on September 12, 2025, issuing 699,158 common shares (19.99% of outstanding) to FITTERS Diversified Berhad as consideration.
• Liquidated its wholly-owned UK biopharmaceutical subsidiary, Cyclacel Limited, on January 24, 2025, resulting in a $4.9 million gain on deconsolidation.
• Sold its remaining biopharmaceutical asset, Plogoserib (Plogo), for $300,000 plus a potential $170,000 milestone payment.
• Reported a net loss of $(2.387) million for the nine months ended September 30, 2025, a significant reduction from $(8.160) million in the prior year.
• Basic and diluted net loss per common share improved to $(2.86) from $(490.01) year-over-year.
• Cash and cash equivalents increased to $3.838 million as of September 30, 2025, from $3.137 million at December 31, 2024.
• Working capital improved significantly from a deficit of $(1.438) million at December 31, 2024, to a surplus of $5.442 million at September 30, 2025.
• Research and development expenses decreased substantially to $0.895 million from $5.775 million due to the business pivot.
• General and administrative expenses increased to $6.467 million from $4.444 million due to one-time costs associated with changes of control.
• Underwent two reverse stock splits: one-for-sixteen on May 12, 2025, and one-for-fifteen on July 7, 2025.
• A legal complaint filed by David Lazar on August 6, 2025, alleging breach of fiduciary duty, minority shareholder oppression, and breach of contract, was voluntarily dismissed without prejudice on August 22, 2025.

Sentiment

Score: 6

Explanation: The company has made significant strides in its strategic pivot, reducing losses and improving liquidity. The divestiture of its high-risk biopharmaceutical assets and acquisition of a revenue-generating fire safety business are positive steps. However, the 'going concern' warning and the need for further capital raises, coupled with integration risks of the new business, temper the overall sentiment. The legal issue was resolved quickly.

Positives

• Net loss significantly reduced to $(2.387) million for the nine months ended September 30, 2025, from $(8.160) million in the prior year.
• Basic and diluted net loss per common share improved substantially to $(2.86) from $(490.01).
• Cash and cash equivalents increased to $3.838 million as of September 30, 2025, from $3.137 million at December 31, 2024.
• Working capital improved from a deficit of $(1.438) million to a surplus of $5.442 million.
• Realized a $4.9 million gain on deconsolidation of the UK subsidiary, Cyclacel Limited.
• Successfully completed the acquisition of Fitters Sdn. Bhd., marking a strategic entry into the fire safety and distribution market.
• Divested the Plogoserib (Plogo) asset for $300,000 upfront, with potential for an additional $170,000 milestone payment, reducing future R&D expenditures.
• Regained compliance with Nasdaq's equity requirement on February 25, 2025.
• A legal complaint by David Lazar was voluntarily dismissed without prejudice.

Negatives

• The company still reports a net loss of $(2.387) million for the nine months ended September 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern, with current cash expected to last only into Q1 2026.
• General and administrative expenses increased by approximately $2.0 million due to one-time costs associated with two changes of control.
• The company is no longer eligible for UK research and development tax credits following the liquidation of its UK subsidiary.
• The company is subject to a Nasdaq Mandatory Panel Monitor until February 25, 2026.
• Significant dilution of existing stockholders occurred due to the issuance of 699,158 common shares (19.99% of outstanding) for the Fitters Sdn. Bhd. acquisition.
• The profitability of the newly acquired Fitters Sdn. Bhd. is yet to be determined if it can sustain the entire group.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to historical losses, negative cash flows, and dependence on additional financing.
• Inability to secure additional funding through equity financing or strategic transactions could lead to curtailment of operations, delays in development, cessation of operations, or bankruptcy.
• Significant dilution of existing stockholders from the issuance of shares for the Fitters Sdn. Bhd. acquisition, potentially depressing the market price of common stock.
• The significant minority position held by FITTERS or its designees may allow them to influence matters requiring stockholder approval, potentially conflicting with other stockholders' interests.
• Failure to realize anticipated benefits from the Fitters Sdn. Bhd. acquisition due to integration challenges, retention issues, or inability to achieve expected synergies.
• Exposure to unknown or contingent liabilities from Fitters Sdn. Bhd., including tax, regulatory, product warranties, intellectual property, environmental, cybersecurity, data privacy, employment, and litigation matters.
• Increased volatility in reported results and potential for significant non-cash charges (e.g., goodwill impairment) due to complex purchase accounting and fair value measurements for the acquisition.
• Increased exposure to regulatory, compliance, cybersecurity, and data privacy risks in new industries and jurisdictions where the company has limited prior experience.
• Challenges in integrating internal controls over financial reporting for Fitters Sdn. Bhd., potentially leading to errors, misstatements, or regulatory scrutiny.
• The Transaction and associated equity issuance may limit strategic flexibility and increase financing risks, potentially constraining growth initiatives.
• Significant resales of common stock by FITTERS or its affiliates, or the perception of such sales, could adversely affect the market price.
• Potential for litigation, regulatory inquiries, or disputes arising from the Transaction, which could be costly and disruptive.
• Adverse tax consequences from the Transaction could increase tax expense and reduce cash flows.
• The combined company may be more exposed to macroeconomic, industry-specific, and geographic risks than its legacy business.

Future Outlook

The company anticipates seeing growth in revenues during the fourth quarter of 2025 following the full integration of Fitters Sdn. Bhd. It does not expect to incur material research and development expenditures prospectively after divesting its biopharmaceutical assets. General and administrative expenditures for the year ended December 31, 2025, are expected to be higher than 2024 due to one-time costs, with a modest increase in overall expenditures in Q4 2025 due to Fitters integration. The company is actively pursuing additional financing through private equity or strategic transactions to address substantial doubt about its ability to continue as a going concern, with current cash projected to last into Q1 2026. The board is considering all viable strategic alternatives, including mergers, acquisitions, or share exchanges, and plans to acquire complementary industrial businesses focusing on bulk commodity minerals and chemicals.

Management Comments

• We anticipate seeing growth in revenues during the fourth quarter of this year [2025] following the full integration of Fitters Sdn. Bhd.
• There remains substantial doubt about our ability to continue as a going concern.
• We are currently investigating ways to raise additional capital through private equity financing or by entering into a strategic transaction.
• Our Board of Directors has begun to analyze strategic alternatives available to the Company to continue as a going concern.
• We plan to acquire complimentary industrial businesses and assets focusing on core manufacturers and suppliers of specific bulk commodity minerals and chemicals distributed to the global manufacturer industry.
• Our consolidation strategy is to assemble a portfolio of mature and value-add industrial commodities businesses to generate a large portfolio of products and services addressing a common and stable customer base.

Industry Context

The company has undergone a complete strategic pivot, exiting the high-risk, capital-intensive biopharmaceutical industry (formerly Cyclacel Pharmaceuticals, Inc.) and entering the more stable, industrial sector of fire safety protection and distribution in Malaysia. This shift aligns with a strategy to acquire "mature and value-add industrial commodities businesses" to capitalize on public vs. private company valuations and access capital markets. This move suggests a de-risking strategy from drug development's long timelines and high failure rates to a business with more immediate revenue generation potential, albeit in a different geographic and market context. The focus on "bulk commodity minerals and chemicals" indicates a broader industrial consolidation strategy beyond just fire safety.

Comparison to Industry Standards

• The company's pivot from biopharmaceuticals to fire safety and distribution makes direct comparison to its former industry peers (e.g., other small-cap biotech firms) largely irrelevant for its new business segment.
• In the biopharmaceutical sector, a net loss of $(2.387) million for nine months, even reduced, would still be typical for a development-stage company, but the complete divestiture of assets means it is no longer comparable.
• For the new fire safety and distribution business in Malaysia (Fitters Sdn. Bhd.), the company anticipates revenue growth in Q4 2025 and expects the subsidiary to be profitable. However, specific comparable companies or industry benchmarks for the Malaysian fire safety market are not provided in the filing to assess performance against.
• The strategy to acquire "complementary industrial businesses" and "assemble a portfolio of mature and value-add industrial commodities businesses" suggests a roll-up strategy, which can be compared to industrial conglomerates or private equity firms executing similar strategies, but no specific comparable entities or projects are mentioned.

Management Changes

Corporate Governance

Legal Proceedings

• On August 6, 2025, David Lazar, a minority shareholder, filed a complaint in the United States District Court Southern District of New York against Bio Green Med Solution, Inc. and Datuk Dr. Doris Wong Sing Ee.
• The complaint alleged three causes of action: (1) breach of fiduciary duty (against Company and Datuk Dr. Wong); (2) minority shareholder oppression (against Datuk Dr. Wong); and (3) breach of contract (against Datuk Dr. Wong).
• Damages requested were $11,882,683.45 for the first and second causes of action, and $629,501.36 for the third cause of action, plus interest and attorneys' fees.
• On August 22, 2025, the plaintiff voluntarily dismissed the complaint without prejudice, concluding the action.

Related Party Transactions

• On January 2, 2025, the company entered into a securities purchase agreement with David E. Lazar (interim CEO and Secretary at the time) to purchase Series C and D Convertible Preferred Stock for $3.1 million.
• On February 11, 2025, David E. Lazar sold his Series C and D Convertible Preferred Stock to Datuk Dr. Doris Wong Sing Ee (who became CEO and majority shareholder).
• In the December 2023 Insider Private Placement, Spiro Rombotis (then CEO) purchased 25 shares of Common Stock and warrants, and Paul McBarron (then EVP-Finance, CFO, COO) purchased 8 shares of Common Stock and warrants.

Stakeholder Impact

• Shareholders: Experienced significant dilution from the Fitters Sdn. Bhd. acquisition (19.99% of common shares issued) and various preferred stock/warrant conversions. The strategic pivot aims for long-term value creation but introduces new risks and uncertainties related to integration and the new business model. The 'going concern' warning remains a significant concern.
• Employees: The liquidation of Cyclacel Limited likely resulted in job losses in the biopharmaceutical segment. The acquisition of Fitters Sdn. Bhd. brings new employees into the company, but integration challenges could impact morale and retention.
• Customers: Customers of Fitters Sdn. Bhd. (fire safety products and services) are now part of the combined entity. The company aims to expand its product and service portfolio, potentially benefiting customers through economies of scale.
• Creditors: Proceeds from capital raises were used to settle outstanding liabilities, which is positive for creditors. The 'going concern' risk, however, indicates potential future challenges in meeting obligations if additional funding is not secured.
• Suppliers: Suppliers of Fitters Sdn. Bhd. are now suppliers to the combined entity. Integration could lead to changes in supplier relationships or terms.

Next Steps

• Full integration of Fitters Sdn. Bhd. to drive revenue growth in Q4 2025.
• Actively pursue additional capital through private equity financing or strategic transactions.
• Evaluate potential business opportunities for acquisition, focusing on complementary industrial businesses in bulk commodity minerals and chemicals.
• Finalize the allocation of the purchase price for Fitters Sdn. Bhd. by the end of the calendar year.
• Continue to evaluate internal controls processes during Fitters integration.
• Board of Directors to continue evaluating quarterly cash dividends on 6% Convertible Exchangeable Preferred Stock.

Key Dates

Recommendation

The company has undergone a radical transformation, exiting a high-risk industry and entering a new one with a clear strategy for industrial consolidation. While the financial results show a significant reduction in losses and improved liquidity, the 'going concern' warning remains a critical concern, indicating a continued reliance on external financing. The successful resolution of the legal dispute and regaining Nasdaq compliance are positive, but the risks associated with integrating a new business, potential dilution, and the need for further capital raises warrant a cautious approach. Investors should hold to observe the execution of the new strategy, the profitability of the acquired fire safety business, and the company's ability to secure necessary funding to alleviate the going concern doubt.

Keywords

Fire Safety, Distribution, Strategic Pivot, SEC Filing, 10-Q, Biopharmaceutical Divestiture, Corporate Restructuring, Merger and Acquisition, Going Concern, Nasdaq Compliance, Malaysia Business, Plogoserib, Cyclacel Limited, Fitters Sdn. Bhd., Equity Financing, Warrant Exchange, Reverse Stock Split